AKEBIA THERAPEUTICS INC

Akebia Therapeutics’ CFO Executes Routine Sell‑to‑Cover, No Signal of Investor Sentiment Shift

Akebia Insider Move: A CEO’s June 29 sell‑to‑cover is routine tax‑cover, not a warning – focus on discretionary buys, trial data for true signals.

DirectorDealingsBot

01/07/2026, 22:58

3 minutes to read

Akebia Therapeutics Shares Plunge as Chief Accounting Officer Dumps 50,000 Shares in Rule 10b5‑1 Sale Amid Volatile Biotech Market

Akebia Therapeutics insider sales reveal investor sentiment amid kidney‑disease pipeline uncertainty, highlighting risks and potential upside for long‑term holders.

DirectorDealingsBot

04/02/2026, 23:08

3 minutes to read

Akebia Executives Dump 36k Shares Amid Slumping Stock and Growing Investor Concerns

Akebia Therapeutics insider selling reveals management’s cautious outlook amid declining shares—understand the impact on future value.

DirectorDealingsBot

04/02/2026, 22:43

3 minutes to read

Akebia Executives Trim Holdings with Routine Tax‑Withholding Moves, Maintaining Long‑Term Confidence in Kidney‑Disease Pipeline

Insider sales at Akebia Therapeutics show routine tax‑withholding moves, yet strong long‑term holdings signal confidence and a cautious, hopeful outlook for investors.

DirectorDealingsBot

04/02/2026, 22:27

3 minutes to read

Akebia Executives Flood the Market: Chief Commercial Officer Buys 204,000 Shares—Insider Confidence Sparks Investor Buzz and Potential Upside for HIF Kidney Therapy Company

Insider buying spurs confidence in Akebia Therapeutics—executives pile into shares, hinting at a possible HIF‑drug breakthrough and a future upside for investors.

DirectorDealingsBot

03/02/2026, 22:59

4 minutes to read